Nicox announces the presentation of scientific data at ARVO 2016
Study results on Nicox compounds presented, including internally-developed pipeline candidates NCX 667, NCX 1653 and NCX 4240, as well as latanoprostene bunod results presented by licensee Bausch + Lomb
...................................
May 9, 2016
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the presentation of seven posters highlighting scientific data for its internally developed and partnered pipeline candidates at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting, one of the key scientific events in the ophthalmology calendar, which was held on May 1-5, 2016 in Seattle, Washington, United States.
Dr. Michael Bergamini, Chief Scientific Officer and Executive Vice President at Nicox, commented: "Beyond latanoprostene bunod and AC-170, for which New Drug Applications are under review with the U.S. Food and Drug Administration (FDA), Nicox has a pipeline of promising and unencumbered ophthalmology assets targeting significant ocular indications, including blepharitis, glaucoma and certain conjunctival disorders. At ARVO this year, in addition to latanoprostene bunod presentations by Bausch + Lomb, Nicox presented three posters on our internally-developed pipeline candidates, NCX 667, NCX 1653 and NCX 4240. These preclinical studies provide early evidence of activity and/or tolerability and reflect our continued commitments to leveraging our proprietary nitric oxide (NO)-donating platform and to creating novel therapeutics to treat ocular diseases."
Details for the poster presentations at ARVO 2016 are as follows and abstracts have been published at the meeting website http://www.arvo.org/AM/Program/ .
Latanoprostene bunod
Title: Long-term Efficacy and Safety of Latanoprostene Bunod 0.024% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies
Date and time: Tuesday, May 3, 2016 from 8:30am - 10:15am PT
Presenter: Jason Vittitow, Bausch + Lomb
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3030 - A0379
Location: Exhibit/Poster Hall
Title: Efficacy of Latanoprostene Bunod 0.024% vs. Timolol Maleate 0.5% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: the LUNAR Study
Date and time: Tuesday, May 3, 2016 from 8:30am - 10:15am PT
Presenter: James Peace, United Medical Research Institute
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3035 - A0384
Location: Exhibit/Poster Hall
Title: Integrated Efficacy of Latanoprostene Bunod 0.024% vs. Timolol Maleate 0.5% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies
Date and time: Tuesday, May 3, 2016 from 8:30am - 10:15am PT
Presenter: Paul Kaufman, University of Wisconsin School of Medicine and Public Health
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3036 - A0385
Location: Exhibit/Poster Hall
Title: Long-term Safety and Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: the JUPITER Study
Date and time: Tuesday, May 3, 2016 from 8:30am - 10:15am PT
Presenter: Kazuhide Kawase, Gifu University Hospital
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3037 - A0386
Location: Exhibit/Poster Hall
Nicox's internally-developed product candidates
Title: IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits
Date and time: Tuesday, May 3, 2016 from 8:30am - 10:15am PT
Presenter: Elena Bastia, Nicox Research Institute
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3031 - A0380
Location: Exhibit/Poster Hall
Title: Intraocular pressure-lowering and ocular exposure of NCX 1653, a novel nitric oxide-donating travoprost in models of ocular hypertension and glaucoma
Date and time: Tuesday, May 3, 2016 from 8:30am - 10:15am PT
Presenter: Francesco Impagnatiello, Nicox Research Institute
Session: Glaucoma clinical studies / Pharmacology
Abstract and poster board #: 3034 - A0383
Location: Exhibit/Poster Hall
Title: Anti-viral efficiency of NCX4240 (iota-carrageenan) eye drops against Adenoviruses (AdV) causing epidemic keratoconjunctivitis (EKC)
Date and time: Wednesday, May 4, 2016 from 3:45pm - 5:30pm PT
Presenter: Brigitte Duquesroix, Nicox
Session: Inflammation
Abstract and poster board #: 5406 - B0146
Location: Exhibit/Poster Hall
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.
Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was submitted to the FDA by the Company's licensee Bausch + Lomb, Valeant Pharmaceuticals International, Inc.'s, wholly owned subsidiary. The Company's pipeline also features AC-170, for which the NDA was submitted to the FDA for the treatment of ocular itching associated with allergic conjunctivitis in April 2016, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.
Nicox is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its commercial products or pipeline, please visit www.nicox.com.
...................................
| Analyst coverage Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France |
Upcoming 2016 events
Financial and business conferences
May 10 Gilbert Dupont Forum Santé Paris, France
May 17 SFAF Bio Day Paris, France
May 19 Lond Capital European Mid Small Cap Forum London, UK
June 6-9 BIO 2016 San Francisco, US
June 28 SGCIB Healthcare & Biotechnology conference Paris, France
July 12-13 Cantor Fitzgerald's 2nd Annual Healthcare conference New York, US
...................................
Contacts
Nicox Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | communications@nicox.com
Media Relations
United Kingdom Jonathan Birt
Tel +44 7860 361 746 | jonathan.birt@ymail.com
France NewCap | Nicolas Merigeau
Tel +33 (0)1 44 71 94 98 | nicox@newcap.eu
United States Argot Partners | Eliza Schleifstein
Tel +1 (917) 763-8106 | eliza@argotpartners.com
Investor Relations
Europe NewCap | Julien Perez | Valentine Brouchot
Tel +33 (0)1 44 71 94 94 | nicox@newcap.eu
United States Argot Partners | Melissa Forst
Tel +1 (212) 600-1902 | melissa@argotpartners.com
...................................
This press release contains certain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2015' filed with the French Autorité des Marchés Financiers (AMF) on April 15, 2016, which is available on Nicox's website (www.nicox.com).
